First reported by Pharmacy Times
<![CDATA[Gedatolisib Combination Approved for PIK3CA Wild-Type HR+, HER2– Breast Cancer]]>
Gedatolisib Combo Approved for Advanced Breast Cancer
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure. Medscape Medical News
Read the full article2d agoen
You might also wanna read
<![CDATA[FDA Approves Gedatolisib for HR+, HER2– PIK3CA Wild-Type Advanced Breast Cancer]]>
CancerNetwork·3d ago
<![CDATA[Managing Gedatolisib IV Delivery and Toxicity Profiles in Breast Cancer]]>
CancerNetwork·1d ago
<![CDATA[Gedatolisib Combination Approved for PIK3CA Wild-Type HR+, HER2– Breast Cancer]]>
Pharmacy Times·3d ago
<![CDATA[Gedatolisib Approval in HR+/HER2- Breast Cancer May Be “Practice Changing”]]>
CancerNetwork·2d ago
FDA Approves Gedatolisib – Based Therapy for HR+/HER2− Advanced Breast Cancer Without PIK3CA Mutation
The U.S. Food and Drug Administration has approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with
OncoDaily·2d ago
The Week in Cancer News: PAM Inhibitor Approved
A targeted therapy inhibits multiple proteins in a common signaling pathway for breast cancer, and disparities researchers feel the impact o
cancertodaymag.org·11h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.